Tag Archive for: tumors

The company announced that a combination of its cancer drugs Zejula and Jemperli, when as used as a maintenance therapy following Jemperli plus chemotherapy, met the main goal of a late-stage trial to treat a certain type of endometrial cancer.

The companies have started a collaboration worth up to $3.4 billion to develop a portfolio of degrader-antibody conjugates, a potentially new class of antibodies that selectively kill cancer cells.

Johnson & Johnson has licensed Nanobiotix’s lead radioenhancer candidate, designed to increase the efficacy of radiation treatment in cancers, capitalizing on the latter’s rocky financial situation.

The companies have reached a deal to discover and develop several targeted radioligand therapies in oncology.

Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.

CytoDyn has spent the past two years under siege – from the FDA, disgruntled investors and by association, the U.S. Department of Justice. Now, the company’s leadership hopes to chart a new future in non-alcoholic fatty liver disease.

All mammography facilities in the country will be required to notify patients about the density of their breast tissues, as that can potentially make detection of tumors more difficult.

Ordaōs and NonExomics announced a research pact to develop mini-proteins, called miniPROs, for three specific difficult-to-target rare cancers.

At the American Society of Clinical Oncology (ASCO)’s annual meeting this weekend, BioNTech and Dr. Vinod Balachandran, M.D. of Memorial Sloan Kettering Cancer Center, presented preliminary Phase I data of its BNT122, which it is evaluating with Genentech (Roche) in pancreatic cancer.

Shares of Repare Therapeutics soared more than 27 percent in premarket trading on June 2 following the previous day’s announcement of a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.